San Francisco, California / ACCESSWIRE / September 29, 2014 / Accurexa Inc. (the "Company") (OTCQB: ACXA) announced today that George Yu, the Company's President & CEO, will co-present with Daniel Lim, M.D., Ph.D., Assistant Professor of Neurological Surgery, University of California, San Francisco (UCSF) at the 4th Annual Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 7-9 in La Jolla, CA.
Organized by the Alliance for Regenerative Medicine (ARM), the California Institute for Regenerative Medicine (CIRM) and the Sanford Consortium for Regenerative Medicine, the 2014 Stem Cell Meeting on the Mesa is a three-day conference aimed at bringing together senior executives and top decision makers in the regenerative medicine industry with the scientific community to advance cutting-edge research into cures. The Partnering Forum, held October 7 and 8 at the Estancia La Jolla Hotel, is the first and only partnering meeting of its kind dedicated solely to facilitating connections for the regenerative medicine and advanced therapies industry.
The meeting also features a nationally recognized Scientific Symposium, held October 9 at the Salk Institute for Biological Studies, showcasing leading academic research in the field of regenerative medicine. Combined, these meetings attract nearly 800 attendees from around the globe, fostering key partnerships through one-on-one meetings while also highlighting clinical and commercial progress in the field.
The following are specific details regarding Accurexa's presentation at the conference:
Event: 2014 Stem Cell Meeting on the Mesa – Partnering Forum
Date: Wednesday, October 8, 2014
Time: 4:45pm PST
Location: La Jolla Ballroom 2, Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037
A live video webcast of all company presentations will be available at: http://stemcellmeetingonthemesa.com/webcast/ and will also be published on ARM's website shortly after the event.
Please visit http://stemcellmeetingonthemesa.com/ for full information including registration. Complimentary attendance at this event is available for credentialed investors and members of the media only. Investors and media should contact Laura Parsons at [email protected].
About Accurexa, Inc.
Accurexa is developing a Radially Branched Deployment (RBD) device for the delivery of stem cells to the human brain which enables the radial deployment of a flexible delivery catheter to large and anatomically complex brain targets through a single initial brain penetration and has the potential to significantly improve the delivery of stem cells into the human brain and enhance the efficacy of a wide range of stem cell therapeutics. Unlike, currently available neurosurgical devices using a straight, rigid needle, Accurexa's RBD device can improve the accuracy of cell delivery, reduce the risk of complications, and increase patient safety.
The RBD device was developed at the University of California, San Francisco (UCSF) with $1.8 million in funding from the California Institute for Regenerative Medicine (CIRM). It is based on a neurosurgical delivery platform which the Company exclusively licensed from UCSF and can be modified for the delivery of a wide range of novel therapeutics and neuromodulation - incl. cells, gene therapy, drugs, drug infusions and electrodes - or developed as a therapeutic-device combination product. Additional information about the Company may be found on its website, http://www.accurexa.com/.
Safe Harbor Statement
This release contains certain "forward-looking statements" relating to the business of the Company. All statements, other than statements of historical fact included herein are "forward-looking statements" including statements regarding: the ability of the Company to perform per its license agreement with UCSF and meet its obligations; the ability of the Company to successfully develop and commercialize the RBD device and execute its business plan; the business strategy, plans, and objectives of the Company; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements.
Contact:
Investor Relations
[email protected]
SOURCE: Accurexa, Inc.